Thomas J Garrity Net Worth

The estimated Net Worth of Thomas J Garrity is at least 1.71 百万$ dollars as of 11 March 2021. Thomas Garrity owns over 50,000 units of Antares Pharma Inc stock worth over 1,533,930$ and over the last 12 years Thomas sold ATRS stock worth over 177,660$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Thomas Garrity ATRS stock SEC Form 4 insiders trading

Thomas has made over 14 trades of the Antares Pharma Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Thomas exercised 50,000 units of ATRS stock worth 56,000$ on 11 March 2021.

The largest trade Thomas's ever made was exercising 80,000 units of Antares Pharma Inc stock on 9 December 2019 worth over 130,400$. On average, Thomas trades about 21,656 units every 130 days since 2012. As of 11 March 2021 Thomas still owns at least 274,406 units of Antares Pharma Inc stock.

You can see the complete history of Thomas Garrity stock trades at the bottom of the page.

What's Thomas Garrity's mailing address?

Thomas's mailing address filed with the SEC is C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300, EWING, NJ, 08628.

Insiders trading at Antares Pharma Inc

Over the last 12 years, insiders at Antares Pharma Inc have traded over 29,755,747$ worth of Antares Pharma Inc stock and bought 910,400 units worth 1,278,090$ . The most active insiders traders include James E Deerfield Mgmt L.P....、James E Deerfield Mgmt L.P....、Jacques Gonella. On average, Antares Pharma Inc executives and independent directors trade stock every 28 days with the average trade being worth of 751,296$. The most recent stock trade was executed by Anton Gueth on 8 July 2021, trading 100,000 units of ATRS stock currently worth 429,000$.

What does Antares Pharma Inc do?

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

Complete history of Thomas Garrity stock trades at Antares Pharma Inc

Antares Pharma Inc executives and stock owners

Antares Pharma Inc executives and other stock owners filed with the SEC include:

• Robert F. Apple,
  CEO, Pres & Director
• Fred M. Powell,
  Exec. VP & CFO
• Peter J. Graham,
  Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Greg Defilippis,
  Sr. VP of Device Bus. & Alliances
• Dr. Jonathan S. Jaffe,
  Interim EVP, Pharmaceutical R&D and Chief Medical Officer
• Dr. Peter Sadowski,
  Sr. VP of Technology Portfolio & Intellectual Property
• Edward Tykot,
  Sr. VP of Corp. Bus. Devel.
• Tram Bui,
  VP of Corp. Communications & Investor Relations
• Keith Muckenhirn,
  Principal Accounting Officer, VP of Fin. & Corp. Controller
• Patrick Madsen,
  Sr. VP of Operations
• Anton Gueth,
  Director
• Robert P Jr Roche,
  Director
• Thomas J Garrity,
  Director
• Fred M Powell,
  Executive Vice President & CFO
• Leonard S Jacob,
  Director
• Marvin Samson,
  Director
• James E Fickenscher,
  Senior Vice President & CFO
• James E Deerfield Mgmt L.P....,
  
• Jacques Gonella,
  Director
• Peter J Graham,
  See Remarks
• James Patrick Tursi,
  EVP, Chief Medical Officer
• Peter Greenleaf,
  Director
• Karen L. Smith,
  Director
• James E Deerfield Mgmt L.P....,
  
• Kaushik J Dave,
  Executive Vice President
• Jennifer Evans Stacey,
  SVP, General Counsel & Secty
• James E Deerfield Mgmt L.P....,
  
• Paul K Wotton,
  President and CEO
• Eamonn P Hobbs,
  Director
• Peter C Richardson,
  See Remarks
• Carmen B Volkart,
  Director
• Robert F Apple,
  President and CEO